Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Recruiting · NCT05748834 · Registry updated 2026-03-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-03-20 | NCT05748834 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Pfizer | 431 |
| SCRI Development Innovations, LLC | 7 |
| Seagen Inc. | 31 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Alliance Cancer Specialists | Bensalem | United States | 2 |
| Blue Ridge Cancer Care (Oncology & Hematology Assoc of SW Virginia, Inc) | Salem | United States | 1 |
| Maryland Oncology Hematology | Columbia | United States | 6 |
| Scri Oncology Partners | Nashville | United States | 156 |
| Tennessee Oncology | Nashville | United States | 77 |
| Texas Oncology- DFW | Dallas | United States | 2 |
| Texas Oncology- San Antonio | San Antonio | United States | 3 |
| Virginia Oncology Associates | Norfolk | United States | 73 |